Gadolinium deposition in tissue after multi-variable MRI scans

Abstract

Mona mohammad, zein eldien Abbas
Corresponding Author : monamohammedmosa@gmail.com

Abstract
Clopidogrel, an oral thinopyridine derivative capable of inhibiting platelet activation. Clopidogrel is a primary drug that is converted into an active drug by hepatocytochrome CYP2C19, CYP2C19 * 2, and CYP2C19 * 3 multifaceted alleles that are considered multifaceted alleles that lead to loss of function resulting in reduced response to clopidogrel. Our study aimed to detect the frequency of CYP2C19 gene pluralism and its impact on clinical outcomes in patients with ischemic heart deficiency taking clopidogrel. Mother and methods: Blood samples were collected from 102 ischemic heart disease patients. Repeated alleles were identified by the polymerase chain reaction and all patients followed clinical assessment and invasive and non-invasive cardiac examinations. The frequency of CYP2C19 * 1 49%, CYP2C19 * 2 was 15% and CYP2C19 * 3 was 1%, CYP2C19 * 17 was 34%, patients with recurrent ischemic seizures 37 patients (35.8%), of these patients, 10 were normal metabolic patients (27%), 27 patients were abnormal metabolites (73%) worth P- 0.047 for myocardial infarction and 0.020 for unstable angina. Conclusion:. An immoral relationship between CYP2C19 multiple shapes and repeated ischemic seizures was found in this study and multi-center studies are required to confirm these results.
Keywords :  clopedogrel, coronary artery disease, genotype.